Analytical Data
-
Gene name
TACR1
- Application
-
Alternative Names
TACR1；NK1R；TAC1R；Substance-P receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25103
-
Expression Region
1-29aa
-
AA Sequence
MDNVLPVDSDLSPNISTNTSEPNQFVQPA
-
Molecular Weight
30.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TACR1, or Tachykinin Receptor 1, is a G-protein coupled receptor primarily involved in mediating the effects of neuropeptides such as substance P and neurokinin A. It plays a crucial role in numerous physiological processes, including pain perception, inflammation, and smooth muscle contraction. The receptor is predominantly expressed in the central and peripheral nervous systems, implicating it in various pathological conditions such as anxiety, depression, and neurodegenerative diseases. Research into TACR1 recombinant proteins has gained significant interest due to their potential therapeutic applications. The ability to produce TACR1 in a recombinant form allows for detailed functional studies and the development of selective ligands that can modulate receptor activity. Additionally, this research facilitates the exploration of TACR1 as a target for drug discovery, aiming to design novel treatments for disorders where tachykinin signaling is dysregulated. Understanding TACR1’s structure and function at a molecular level enables scientists to identify key mechanisms of action and inform the development of strategies for clinical intervention. Overall, the study of TACR1 recombinant proteins is essential for elucidating the complexities of tachykinin signaling and advancing therapeutic approaches in neurology and pain management.
